Dentium CO., LTD (KRX:145720)
South Korea · Delayed Price · Currency is KRW 37,550
+300 (0.81%)
At close: Sep 4, 2026
Dentium CO., LTD Revenue
Dentium CO., LTD had revenue of 89.35B KRW in the quarter ending June 30, 2026, with 8.62% growth. This brings the company's revenue in the last twelve months to 348.09B, down -6.55% year-over-year. In the year 2025, Dentium CO., LTD had annual revenue of 346.45B, down -15.05%.
Revenue (ttm)
348.09B
Revenue Growth
-6.55%
P/S Ratio
0.67
Revenue / Employee
408.08M
Employees
853
Market Cap
232.02B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 346.45B | -61.36B | -15.05% |
| Dec 31, 2024 | 407.81B | 14.62B | 3.72% |
| Dec 31, 2023 | 393.19B | 37.32B | 10.49% |
| Dec 31, 2022 | 355.87B | 64.34B | 22.07% |
| Dec 31, 2021 | 291.53B | 61.78B | 26.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Samsung Epis Holdings | 1.51T |
| Suheung | 765.90B |
| Huons | 607.75B |
| Samjin Pharmaceuticals | 274.03B |
| ALTEOGEN | 254.01B |
| Vieworks | 244.28B |
Dentium CO., LTD News
- 22 days ago - Dentium CO., LTD Quarterly report: Q2 2026 - Filings
- 3 months ago - Dentium CO., LTD Slides: Q1 2026 - Filings
- 5 months ago - Dentium CO., LTD Slides: Q4 2025 - Filings
- 5 months ago - Dentium CO., LTD Annual report: Q4 2025 - Filings
- 9 months ago - Dentium CO., LTD Slides: Q3 2025 - Filings
- 9 months ago - Dentium CO., LTD Quarterly report: Q3 2025 - Filings